Clinical Trials in China / NCT06369935
Starting soon
Observational
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
NCT06369935 · tracked via the Priya Life Science China tracker
Condition(s) studied
Relapsed/Refractory Multiple Myeloma
Investigational drug(s) / intervention(s)
Equecabtagene Autoleucel: Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
Study summary
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
Eligibility
Inclusion Criteria:
* Adult patients with confirmed relapsed/refractory multiple myeloma;
* Based on clinical practice, the physician decided to administer equecabtagene autoleucel treatment;
* Voluntarily sign the informed consent form approved by the ethics committee.
Exclusion Criteria:
* Patients who are hypersensitive to the active ingredients of the product or any excipients (dimethyl sulfoxide, compound electrolyte injection, human albumin);
* The researcher believes that patients are unable to return for follow-up visits or that it is impossible to complete the study;
* Patients with expected survival less than 3 months
Primary outcome measure(s)
- Best Overall Response Rate， BOR — up to 24 weeks
Patients treatmented with Equecabtagene Autoleucel, the optimal disease state evaluated by the researcher is strict complete response (sCR),complete response (CR), very good partial response (Very Good Partial Response (VGPR) or partial response (partial response,PR) rate.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peking University People's Hospital | Beijing | China |
More Peking University People's Hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06369935 on ClinicalTrials.gov ↗ ← All trials in China